Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

whilst “American” Merck (now Merck & Co. in the US or Merck Sharp & Dohme (MSD) elsewhere) was compulsorily split off from its Germany parent company (Merck KGaA) at the same time. Bayer also ...

European stocks closed broadly lower on Monday after a cautious session as investors awaited the monetary policy announcements from ...

Stocks today are moderately higher, recovering some of last Friday’s sharp sell-off as chip stocks move higher ... is down more than -2% to lead losers in the Dow Jones industrials. Merck & Co (MRK) ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: September 20 at 7:52 PM EDT Loading Chart for MRK ...